AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03814226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of headache inducing capabilities of PACAP38
Description: We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
Study NCT03814226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of headache inducing capabilities of PACAP38
Description: We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
Study NCT01386632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCA (dichloroacetate)
Description: DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
Study NCT01386632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
Study NCT03684460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daytime Bright Light
Description: Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
Study NCT03684460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Light
Description: Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2.
Study NCT03070262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA
Description: caffeic acid, 300mg, tid, po
Study NCT03070262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: placebo tablet, 3 tablets, tid, po
Study NCT02117024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagenpumatucel-L
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
Study NCT02117024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic Cyclophosphamide
Description: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
Study NCT02117024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
Description: Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed
Study NCT02094339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local analgesic
Description: Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
Study NCT02094339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block
Description: Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
Study NCT02094339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous analgesic
Description: People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
Study NCT02094339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 0.2% ropivacaine
Study NCT02094339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: 0.2% ropivacaine
Study NCT02094339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid
Description: flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
Study NCT04572464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Guided Meditation
Description: Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
Study NCT04778995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured online training program for effective management of nursing services
Description: An online structured training program was prepared to reach out to manager nurses for increasing their knowledge regarding the effective management of nursing services in crisis periods. A web page was structured with the support of a professional computer engineer.~Participant manager nurses could log into the system via a personal username and password on the main login screen of the site. In this page, there is an Informed Consent Form.~In the Download Training Documents link; the educational content prepared in sections was presented. Educational content consisted of the issues such as: Management of Crises and Emergency Situations, Leadership in Crisis, Planning and Managing Nurse Human Power in Crisis, Supervision and Management of Patient Care, Logistics and Support Services, Communication in Extraordinary Situations, Motivation Tools Used in Extraordinary Situations, Stress Management During Crisis and Employee Adaptation and Training in Crisis.
Study NCT03268395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Arterial Blood Gas and Transcutaneous CO2 Monitor
Description: Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
Study NCT00688649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Nutritional Supplement (ONS)
Description: Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
Study NCT00688649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High energy Oral Nutritional Supplement (ONS)
Description: High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
Study NCT01591044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 puff bid or 2 puffs bid
Study NCT01591044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R940343 1mg
Description: R343 1mg, 1 puff bid
Study NCT01591044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R940343 2mg
Description: R343 2mg, 2 puffs bid
Study NCT03770078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: The test product is a newly developed ostomy product
Study NCT00799370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early weight bearing
Description: Weight bearing performed immediately after surgery
Study NCT00799370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed weight bearing
Description: Weight bearing performed 2 months after surgery
Study NCT04093115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1106
Description: administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
Study NCT01990339 — intervention group
Intervention type: DRUG
Intervention: Lansoprazole
Description: • Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
Study NCT02949297 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ovation Alto Abdominal Stent Graft System
Description: Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
Study NCT00674037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monetary incentive
Description: 75 euros for each patient included
Study NCT02929758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed of processing training (SOPT)
Description: This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
Study NCT02929758 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Speed of processing training (SOPT)
Description: This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
Study NCT01043614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER group intervention
Description: An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
Study NCT00089609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.
Study NCT00089609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 200 mg by mouth daily throughout the cycle.
Study NCT04293081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preemptive chlorepheniramine maleate intravenous injection
Description: Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
Study NCT04293081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
Study NCT01741285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone (QVAR)
Description: Small particle treatment
Study NCT00089609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 10 mg by mouth daily throughout the cycle.
Study NCT01741285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone (Clenil)
Description: Course particle beclomethasone
Study NCT01741285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone (Clenil)
Description: Course particle beclomethasone
Study NCT01741285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Course particle treatment
Study NCT02806115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acetic acid-enhanced endoscopy
Description: Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
Study NCT02806115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetic Acid
Description: The concentration of acetic acid used in this study is 1.5%.
Study NCT02806115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscope
Description: This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
Study NCT00089609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
Study NCT00089609 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.
Study NCT00089609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.
Study NCT00089609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.
Study NCT00089609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
Study NCT02795247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cruciate Ligament Reconstruction
Study NCT02643368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV2 at 6 and 7 weeks of age
Description: Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
Study NCT02643368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV2 at 6 and 8 weeks of age
Description: Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
Study NCT02643368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV2 at 6 and 10 weeks of age
Description: Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
Study NCT02643368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 6 weeks of age
Description: Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
Study NCT03337022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006
Description: CC-90006
Study NCT00702988 — intervention group
Intervention type: DRUG
Intervention: Org 36286
Description: single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
Study NCT00702988 — intervention group
Intervention type: DRUG
Intervention: recFSH
Description: 150 IU recFSH daily (reference group administered under protocol 38826)
Study NCT00717288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir dosed at 50% of calculated basal insulin infusion requirements
Study NCT00717288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir dosed at 65% of calculated basal insulin infusion requirements
Study NCT00717288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir dosed at 80% of calculated basal insulin infusion requirements
Study NCT02995408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for Parents of Children with ASD
Study NCT03337022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01452867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bag-Valve-Mask-Ventilation (Ambu Facemask)
Description: Bag-Valve Mask-Ventilation
Study NCT01452867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask (Laryngeal Mask Airway Supreme)
Description: Ventilation
Study NCT01452867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))
Description: Ventilation
Study NCT04918394 — intervention group
Intervention type: OTHER
Intervention: Questionnaire of Mold / moisture exposure
Description: Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home:~* Presence of visible mold~* Impression of dampness~* Apparent dampness~* Existence of recent water damage in the last year~* Presence of a moldy odor
Study NCT01366976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1g every 6 hours for 4 doses over 24 hours
Study NCT01366976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1g every 6 hours for 4 doses over 24 hours
Study NCT01181115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: Interferon treatment for MS
Study NCT04552457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No activity restrictions
Description: Patients in the No activity restrictions group will be allowed to return to their normal activity immediately.
Study NCT04552457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity restrictions
Description: Patients in the Activity restrictions group will not be allowed to perform strenuous exercise or lift anything greater than 10lbs. Strenuous exercise will be defined as is any activity that requires so much exertion that one cannot have a conversation comfortably while doing it.
Study NCT03482102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
Study NCT03482102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
Study NCT01741285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Course particle treatment
Study NCT03482102 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy is used to shrink cancer cells.
Study NCT04540926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
Study NCT04119947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-009
Description: The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
Study NCT04119947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SY-009
Description: The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
Study NCT03055598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Description: Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
Study NCT04330612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative Updates
Description: In the intervention group, the families received additional standardized electronic updates via pagers at three pivotal moments: 1) Initial skin incision has been made; 2) Critical part of the case is completed and closure has begun; and, 3) Closure is complete, and patient will be transferred to the recovery room when ready.
Study NCT02051218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (reduced dosing)
Description: 3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
Study NCT02051218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab (standard dosing)
Description: Denosumab 120mg (XGEVA®) sc. q4w